Recombinant Rhesus Macaque CD19 (C-Fc)

Description

EnkiLife provides the Recombinant Rhesus Macaque CD19 (C-Fc) protein,aslo know as B-Lymphocyte Antigen CD19,B-Lymphocyte Surface Antigen B4,Differentiation Antigen CD19,T-Cell Surface Antigen Leu-12,CD19, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Rhesus Macaque CD19 Molecule is produced by our Mammalian expression system and the target gene encoding Pro20-Lys292 is expressed with a human IgG1 Fc tag at the C-terminus.Accession:F7F486. Expression Host:Human Cells.Species:Rhesus macaque.Predicted Molecular Mass:57.2 KDa. Background:CD19 is a single-pass type I membrane protein containing 2 Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. CD19 primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. CD19 Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) which is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.